Protective human antibodies target West Nile and related viruses

· Medical Xpress

by Istituto di Ricerca in Biomedicina

edited by Stephanie Baum, reviewed by Robert Egan

Stephanie Baum

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Associate Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

The GIST Add as preferred source

Molecular reconstruction of WNV and mechanism of binding by virus neutralizing antibodies reported in the study. Credit: Christopher Barnes and Zaira Contejean, Stanford University

West Nile virus (WNV) is transmitted by mosquitoes and is increasingly relevant for Europe and worldwide. It can cause severe brain infection and death, yet there is no specific antiviral treatment or approved human vaccine. A collaborative study published in Immunity analyzed blood from WNV convalescents in Serbia to understand antibody immune responses and identify protective human monoclonal antibodies with potential to prevent or treat WNV and related orthoflavivirus infections.

Davide Robbiani's laboratory at the Institute for Research in Biomedicine (IRB, affiliated with Università della Svizzera italiana) in Bellinzona, Switzerland, together with international collaborators, identified monoclonal antibodies that may help address this unmet medical need.

Among them, antibody W010 recognizes a distinct site on the virus envelope domain III, a key surface protein involved in viral attachment and infection. W010 protected mice when administered before and even 5 days after exposure to WNV. A second antibody, W014, showed broader cross-neutralization against pathogenic orthoflaviviruses, including Japanese encephalitis, Murray Valley encephalitis, St. Louis encephalitis and Usutu viruses.

The findings define vulnerable sites on WNV that could inform vaccine development and highlight antibody candidates with prophylactic and therapeutic potential. They may also guide interventions for a wider group of encephalitic orthoflavivirus infections.

Publication details

Tomás Cervantes Rincón et al, Analysis of West Nile disease convalescents identifies human monoclonal antibodies protective against West Nile and related orthoflaviviruses, Immunity (2026). DOI: 10.1016/j.immuni.2026.05.013

Journal information: Immunity

Key medical concepts

West Nile virus

Clinical categories

Infectious diseasesClinical pharmacology Provided by Istituto di Ricerca in Biomedicina Who's behind this story?

Stephanie Baum

Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Protective human antibodies target West Nile and related viruses (2026, June 22) retrieved 23 June 2026 from https://medicalxpress.com/news/2026-06-human-antibodies-west-nile-viruses.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.